A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: Immunological studies

European Cytokine Network

Volumn 4, Issue 3, 1993, Pages 205-211

  Ghosh, A K ^a   Smith, N K ^a   Prendiville, J ^a   Thatcher, N ^a   Crowther, D ^a   Stern, P L ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Immunological effects; Interleukin 4; Phase I study

Indexed keywords

CYTOKINE; HLA ANTIGEN CLASS 2; LYMPHOCYTE SURFACE MARKER; MITOGENIC AGENT; RECOMBINANT INTERLEUKIN 4;

ANTIGEN EXPRESSION; ARTICLE; CANCER; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; HUMAN; IMMUNOLOGICAL PARAMETERS; INTRAVENOUS DRUG ADMINISTRATION; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; HUMAN; IMMUNOPHENOTYPING; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MITOGENS; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0027297088     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)